Success Story: NIW Approval for a Pharmaceutical Scientist Advancing Safer and More Effective Drug Formulations
Client’s Testimonial:
"Chen immigration did a wonderful job with my EB2 NIW petition. They were very communicative, responsive, and were very knowledgeable about the entire filing process. They were also well updated on the trends in the EB1/2 approvals and communicated the best thing to do to increase the chance of approval. I would highly recommend the Chen Immigration group for people with a good research background who are considering the EB1/EB2 petitions.”
On June 11th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Scientist
Country of Origin: China
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: June 11th, 2026
Processing Time: 12 months, 19 days (Premium Processing Requested)
Case Summary:
“Based on [the client]’s groundbreaking work, her expertise is unmistakable, offering immense benefits to drug efficacy.”
This expert statement captured the central strength of the client’s EB-2 NIW case. The client, a scientist in pharmaceutical sciences from China, proposed to continue developing advanced pharmaceutical formulation strategies across diverse drug delivery platforms. This work aims to accelerate the translation of novel therapeutic molecules from the preclinical phase into clinical trials, ultimately resolving critical bottlenecks in patient care and addressing unmet medical needs.
North America Immigration Law Group (Chen Immigration Law Associates) prepared the petition around the practical value of the client’s work in drug delivery. Rather than presenting the case only as a publication record, our team emphasized how the client’s research addressed major formulation challenges, including poor solubility, limited bioavailability, unwanted side effects, and the need for scalable delivery systems. The petition connected this work to U.S. needs in pharmaceutical innovation, national health, Alzheimer’s treatment development, drug supply resilience, and the growth of the pharmaceutical market.
The evidence showed that the client had developed a strong record in pharmaceutical sciences. The client documented 12 peer-reviewed journal articles, 8 first-authored conference abstracts, and 1 first-authored book chapter. Their work had received 285 citations, and 7 papers ranked among the most highly cited in Pharmacology & Toxicology for their respective publication years, including 2 papers in the top 1% and 5 papers in the top 10%. These metrics helped demonstrate that the client’s findings had been independently relied upon by other researchers in the field.
Additional evidence further supported the client’s positioning to advance the proposed endeavor. The client had completed at least 35 peer reviews for authoritative journals. The petition was also supported by 4 recommendation letters and showed that the client’s expertise was recognized through both scholarly reliance and professional service in the pharmaceutical sciences community.
USCIS approved the NIW petition on June 11th, 2026, after 12 months and 19 days, with Premium Processing upgraded on April 15th, 2026. We congratulate this pharmaceutical scientist on this important approval and are honored that we could support a petition demonstrating how advanced drug formulation research can contribute to safer therapies, stronger drug efficacy, and improved patient outcomes in the United States.